Community curated by people like you

Targeted cancer chemotherapy stories

Nov 4, 2026

Sino Biopharmaceutical signs cancer deal worth up to $7 billion with Boehringer Ingelheim

Sino Biopharmaceutical entered an option and license agreement with Germany's Boehringer Ingelheim for six pre-clinical oncology programs that could generate up to approximately $7 billion in total value.

Nov 4, 2026·3 sources

00

Top claims

▪Boehringer Ingelheim GmbH is Germany's largest pharmaceutical company by sales, ahead of Bayer AG
▪The six preclinical biologic programs licensed by Boehringer Ingelheim GmbH from Sino Biopharmaceutical Limited include T-cell engagers, designed to activate and direct immune cells to destroy cancer cells
▪Sino Biopharmaceutical Limited will conduct early development for all six preclinical biologic oncology programs covered in a cancer drug licensing deal signed on November 4, 2026 with Boehringer Ingelheim GmbH

Subtopics

Cancer & Oncology1 Cancer immunotherapy1 Drug development1 Hong Kong1 Pharmaceutical Industry1

Related timelines

AI Data Center Gold Rush

Congress

Iran War

Strait of Hormuz blockage

Trump administration